Proceedings of the 5th International Conference on Economics, Management, Law and Education (EMLE 2019)

Research on Social Responsibility Information Disclosure and Performance of Pharmaceutical Companies: Based on the Perspective of Institutional Investor Governance

Authors
Gang Chen
Corresponding Author
Gang Chen
Available Online 7 January 2020.
DOI
https://doi.org/10.2991/aebmr.k.191225.111How to use a DOI?
Keywords
pharmaceutical companies, corporate social responsibility, institutional investors holding shares, equity concentration
Abstract
In recent years, China’s medical product safety accidents have occurred in an endless stream, causing widespread public concern about the social responsibility of pharmaceutical companies. As an important external supervision body in corporate governance, institutional investors play a key role in promoting pharmaceutical companies to assume social responsibility. This paper analyzes the status quo of medical enterprise social responsibility information disclosure by obtaining the list of pharmaceutical manufacturing listed companies with RKS CSR Ratings, and further discusses the influence of institutional investors’ shareholding on corporate social responsibility performance from the perspective of institutional investor governance. The study found that the overall level of social responsibility information disclosure of pharmaceutical companies in China is not high, but there is an improvement trend; in terms of social responsibility performance, institutional investors can play a significant positive impact; moreover, compared with the companies with higher ownership concentration, the shareholding of institutional investors in the companies with lower ownership concentration can play a more positive role in promoting companies to fulfill their social responsibilities.
Open Access
This is an open access article distributed under the CC BY-NC license.

Download article (PDF)

Cite this article

TY  - CONF
AU  - Gang Chen
PY  - 2020
DA  - 2020/01/07
TI  - Research on Social Responsibility Information Disclosure and Performance of Pharmaceutical Companies: Based on the Perspective of Institutional Investor Governance
BT  - Proceedings of the 5th International Conference on Economics, Management, Law and Education (EMLE 2019)
PB  - Atlantis Press
SP  - 615
EP  - 621
SN  - 2352-5428
UR  - https://doi.org/10.2991/aebmr.k.191225.111
DO  - https://doi.org/10.2991/aebmr.k.191225.111
ID  - Chen2020
ER  -